US · Healthcare · Biotechnology
EPS came in at -0.36 against a street estimate of -0.71 — a beat of 49.3%.
Analysts rate Spyre Therapeutics Inc. a strong buy (16 buy, 1 hold, 0 sell out of 17) with an average price target of $120.21.
| Fund | Stake |
|---|---|
| FMR Inc | 14.58% |
| BlackRock Inc | 7.28% |
| Perceptive Advisors LLC | 4.84% |
| RTW INVESTMENTS, LLC | 4.76% |
| Paradigm Biocapital Advisors LP | 4.30% |
| Vanguard Capital Management, LLC | 3.86% |
| State Street Corp | 3.42% |
| VR Adviser, LLC | 3.34% |
| Document | Date |
|---|---|
| Material agreement · Q4 2026 HEADLINE NUMBERS • Spyre Therapeutics agreed to sell 4,117,648 shares of common stock at $85.00 per share. • Expected gross proceeds are approximate | 2026-10-07 |
| Reg FD disclosure · Q3 2026 SPYRE THERAPEUTICS, INC. - DOCUMENT SUMMARY HEADLINE NUMBERS • SPY003 Primary Endpoint Met: 10.0-point reduction in Robarts Histopathology Index (RH | 2026-09-08 |
| Reg FD disclosure · Q3 2026 SPYRE THERAPEUTICS, INC. – DOCUMENT SUMMARY HEADLINE NUMBERS • SPY072 Low Dose: -1.9 point change in DAS28-CRP at Week 12 (statistically significant | 2026-08-25 |
| Quarterly report · Q2 2026 SPYRE THERAPEUTICS, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash and marketable securities: $1,145.3 million as of June 30, 2026 (up from $75 | 2026-08-04 |
| Results announced · Q3 2026 SPYRE THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position of $1,145.3 million ($162.0 million cash + $983.3 million mark | 2026-08-04 |
| Reg FD disclosure · Q2 2026 SPYRE THERAPEUTICS, INC. – FORM 8-K SUMMARY Date of Report: June 15, 2026 --- HEADLINE NUMBERS • Primary Endpoint Met: SPY002 achieved a statistica | 2026-06-15 |
| Quarterly report · Q1 2026 SPYRE THERAPEUTICS, INC. - Q1 2026 SUMMARY HEADLINE NUMBERS • Cash Position: $97.2 million cash + $644.3 million marketable securities = $741.5 mill | 2026-05-05 |
| Proxy statement · Q2 2026 SPYRE THERAPEUTICS, INC. — 2026 PROXY STATEMENT SUMMARY --- CEO COMPENSATION & CHANGE • Cameron Turtle (CEO) total compensation: Not explicitly sta | 2026-04-10 |
Readable in the app.
| Announcement | Date |
|---|---|
| Expanded license agreement field of use with Paragon Therapeutics Spyre Therapeutics expanded the commercial rights to its SPY003 drug candidate on May 29, 2026. Originally limited to inflammatory bowel disease (IBD), the company can now pursue SPY003 in a | 2026-06-01 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Spyre Therapeutics Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.